Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

September 4, 2024

Axsome Therapeutics announces FDA acceptance of NDA resubmission for AXS-07, a novel oral medicine for acute migraine treatment, with a PDUFA goal date of January 31, 2025.

Highlighted Terms

rizatriptan American Migraine Foundation AXS-07 U.S. Food and Drug Administration Migraine meloxicam Axsome Therapeutics

Related News

drugs.com

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

Axsome Therapeutics announces FDA acceptance of NDA resubmission for AXS-07, a novel oral medicine for acute migraine treatment, with a PDUFA goal date of January 31, 2025.